Core Viewpoint - TG Therapeutics, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, highlighting its ongoing engagement with investors and the healthcare community [1]. Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [3]. - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis (RMS) [3]. - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for treating adult patients with RMS in Europe and the United Kingdom [3]. Event Details - The fireside chat with Michael S. Weiss is scheduled for June 10, 2025, at 10:40 am ET during the conference held in Miami, FL [1]. - A live webcast of the fireside chat will be available on the company's website [2].

Summary of TG Therapeutics Conference Call Company Overview - **Company**: TG Therapeutics (TGTX) - **Event**: 2025 Jefferies Global Healthcare Conference - **Focus**: CD20 MS (Multiple Sclerosis) treatment pipeline Key Points on CD20 MS Market - **Market Dynamics**: The CD20 market is the leading treatment for MS patients, with a dynamic market share of approximately 50-55% for new starts, indicating growth from previous levels around 50% [5][20] - **Shift in Treatment**: Younger MS clinicians are more inclined to use CD20 therapies, which is expected to increase patient adoption [5][6] - **IV vs. Subcutaneous (SubQ)**: - IV remains the leading mode of delivery, but SubQ is growing, currently accounting for about 35-40% of new starts [7][15] - SubQ products are gaining traction due to convenience and cost-effectiveness compared to IV infusions at academic centers [8][9] - **Future Expectations**: The overall CD20 market is expected to continue growing, with no significant threats to its position in the near term [21][24] TG Therapeutics' Positioning - **Market Share Goals**: TG Therapeutics aims to become the number one player in the CD20 market, currently positioned at number three [27][28] - **Competitive Advantages**: - TG's product is priced as the lowest branded treatment for MS, which is a key driver for market share growth [29] - The company emphasizes having a strong team with an average of 12 years of experience in MS [30] - **Marketing Strategy**: The marketing approach focuses on targeting impactful clinicians and expanding outreach [40][41] Product Development and Innovations - **Enhanced Regimen**: TG is working on a combined dosing regimen to improve patient convenience, aiming for a pivotal trial to start soon [53][54] - **SubQ Development**: Plans for a SubQ product are underway, with potential for every other month dosing, which would be less frequent than the current monopoly product [62][66] - **Timeline for SubQ**: Expected to start pivotal studies soon, with potential filing by mid-2027 and approval by mid-2028 [66][70] Financial Outlook - **Revenue Growth**: TG anticipates revenue growth from $310 million last year to approximately $560 million this year, while keeping operational expenses relatively stable [72][73] - **Focus on Top-Line Growth**: The company is prioritizing revenue growth over immediate profitability, with no current focus on bottom-line metrics [78][79] Additional Insights - **Patient Awareness**: Awareness of TG's product, Brionvi, is currently around 30%, compared to over 70% for competitors, indicating room for improvement [43][44] - **DTC Marketing**: The company has initiated direct-to-consumer marketing efforts to enhance product awareness [45][46] - **Long-Term Strategy**: TG is open to exploring new opportunities and indications beyond MS, which may impact future operational expenses [76][77]

Core Insights - TG Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, with a fireside chat scheduled for June 4, 2025, at 12:50 PM ET [1] Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis (RMS) [3] - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for treating adult patients with RMS who have active disease [3]

Core Insights - TG Therapeutics presented data on BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting [1][2] - The company is optimistic about the ongoing data presentations throughout the year [2] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI approved for RMS treatment in the U.S., Europe, and the UK [23] - The company has a pipeline of investigational medicines in addition to BRIUMVI [23] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to deplete B-cells efficiently at low doses through glycoengineering [4] - It is indicated for adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [5] Clinical Trials - The ULTIMATE I & II trials involved 1,094 RMS patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3] - The trials required patients to have experienced at least one relapse in the previous year or two relapses in the previous two years, with specific EDSS score criteria [3] Safety and Efficacy Data - Presentations at the CMSC included findings on the safety and tolerability of BRIUMVI, with a focus on infusion reactions and immunoglobulin levels [2][6] - The incidence of infusion reactions in BRIUMVI-treated patients was reported at 48%, with serious reactions occurring in 0.6% of patients [6][8] - The overall infection rate in BRIUMVI-treated patients was 56%, with serious infections at 5% [8] Market Context - Relapsing multiple sclerosis affects nearly 1 million people in the U.S., with 85% initially diagnosed with relapsing-remitting forms [22] - The global prevalence of MS is over 2.3 million [22]

Company Overview - TG Therapeutics (NASDAQ: TGTX) is a commercial stage biotech company focused on Briumvi, a treatment for multiple sclerosis [1] Investment Strategy - The investment approach involves careful analysis of earnings reports to identify potential growth opportunities, with past successes including companies like OPRX, OTRK, FUBO, and PLUG [1]

Core Insights - TG Therapeutics, Inc. announced the presentation schedule for BRIUMVI (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, focusing on its efficacy in patients with relapsing forms of multiple sclerosis (RMS) [1][2] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI approved for treating adult patients with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [24][25] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed through glycoengineering to enhance B-cell depletion at lower doses [4] - The drug is indicated for adults with RMS, which includes various forms of the disease [6] Clinical Trials - The ULTIMATE I & II Phase 3 trials involved 1,094 patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3] - Patients in these trials had experienced at least one relapse in the previous year or had specific MRI findings [3] Presentation Details - Presentations at the CMSC meeting include topics on the safety and tolerability of BRIUMVI, with specific focus on infusion reactions and real-world observational data [2][5]

[Special Cautionary Notice Regarding Forward-Looking Statements](index=3&type=section&id=SPECIAL%20CAUTIONARY%20NOTICE%20REGARDING%20FORWARD-LOOKING%20STATEMENTS) This section cautions that the report contains forward-looking statements subject to safe harbor provisions, where actual results may differ materially due to various risks [Special Cautionary Notice Regarding Forward-Looking Statements](index=3&type=section&id=SPECIAL%20CAUTIONARY%20NOTICE%20REGARDING%20FORWARD-LOOKING%20STATEMENTS) This section details the report's forward-looking statements, which are subject to safe harbor provisions and involve known and unknown risks that could cause actual results to differ materially - The report's forward-looking statements are protected under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995[9](index=9&type=chunk) - Key areas covered by forward-looking statements include regulatory approvals for products like BRIUMVI and azer-cel, commercialization success, manufacturing reliability, financial projections, capital requirements, and competitive developments[10](index=10&type=chunk) [Summary Risk Factors](index=4&type=section&id=SUMMARY%20RISK%20FACTORS) This section provides a high-level overview of principal risks associated with investing in the company, categorized by commercialization, financial, and operational areas [Summary Risk Factors](index=4&type=section&id=SUMMARY%20RISK%20FACTORS) This section summarizes the principal risks of investing in the company, covering commercialization, financial position, drug development, regulatory, third-party dependence, and intellectual property challenges - Commercialization risks include achieving market acceptance for BRIUMVI, facing substantial competition, and potential product liability lawsuits[12](index=12&type=chunk)[15](index=15&type=chunk) - Financial risks highlighted are a history of significant operating losses, potential future need for additional capital, and the adverse effects of indebtedness[13](index=13&type=chunk)[15](index=15&type=chunk) - Drug development and regulatory risks involve the uncertainty of obtaining and maintaining approvals, the potential for undesirable side effects, and navigating extensive and costly regulations[13](index=13&type=chunk)[15](index=15&type=chunk) - The company is heavily reliant on third parties for manufacturing, clinical trials, and in-licensed products, which poses significant operational risks[16](index=16&type=chunk)[20](index=20&type=chunk) - Intellectual property risks center on the ability to obtain, protect, and enforce patents and trade secrets, which is critical for commercial success[17](index=17&type=chunk)[20](index=20&type=chunk) [PART I: Financial Information](index=6&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) This part presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis for the quarter ended March 31, 2025 [Item 1. Financial Statements](index=6&type=section&id=Item%201%20Financial%20Statements%3A) This section presents the unaudited condensed consolidated financial statements for Q1 2025, showing a net income of **$5.1 million** driven by strong product revenue growth [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets increased to **$656.7 million**, driven by higher accounts receivable and inventories, while total liabilities also rose to **$419.4 million** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $132,139 | $179,894 | | Accounts receivable, net | $190,121 | $129,185 | | Inventories | $157,759 | $110,458 | | **Total Assets** | **$656,689** | **$577,690** | | **Liabilities & Equity** | | | | Accounts payable and accrued expenses | $133,932 | $58,296 | | Loan payable – non-current | $244,733 | $244,429 | | **Total Liabilities** | **$419,400** | **$355,326** | | **Total Stockholders' Equity** | **$237,289** | **$222,364** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20%28unaudited%29) For Q1 2025, the company achieved profitability with a net income of **$5.1 million**, a significant improvement from a **$10.7 million** net loss in Q1 2024, driven by a **137%** increase in net product revenue Statement of Operations Summary (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Product revenue, net | $119,655 | $50,488 | | Total revenue | $120,856 | $63,474 | | Total costs and expenses | $112,234 | $72,744 | | Operating income (loss) | $8,622 | ($9,270) | | Net income (loss) | $5,060 | ($10,707) | | Diluted net income (loss) per share | $0.03 | ($0.07) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20%28unaudited%29) Net cash used in operating activities for Q1 2025 increased to **$28.7 million**, primarily due to higher accounts receivable and inventory, resulting in a **$47.8 million** net decrease in cash Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($28,715) | ($8,207) | | Net cash used in investing activities | ($12,934) | ($9,255) | | Net cash (used in) provided by financing activities | ($6,102) | $10 | | **Net Decrease in Cash** | **($47,751)** | **($17,452)** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements%20%28unaudited%29) The notes provide detailed explanations of the company's accounting policies and financial statement line items, including revenue recognition, inventory valuation, debt facilities, and significant license agreements - The company is a commercial-stage biopharmaceutical firm focused on B-cell diseases, with BRIUMVI approved in the US, EU, and UK for relapsing forms of multiple sclerosis (RMS)[32](index=32&type=chunk) - As of March 31, 2025, the company had **$276.2 million** in cash, cash equivalents, and short-term investments, which is anticipated to be sufficient for more than twelve months of operations[35](index=35&type=chunk) - In August 2024, the company entered into a new **$250 million** term loan facility with Blue Owl Capital, refinancing its previous debt[100](index=100&type=chunk) - The company has a commercialization agreement with Neuraxpharm for BRIUMVI outside the US, receiving **$140 million** upfront and a **$12.5 million** milestone payment, with potential for up to **$492.5 million** in additional milestones[114](index=114&type=chunk) - In January 2024, the company licensed azer-cel, an allogeneic CAR T therapy, from Precision BioSciences for autoimmune diseases, with an upfront payment of **$7.5 million** and potential for **$288 million** in future milestones[118](index=118&type=chunk)[119](index=119&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=28&type=section&id=Item%202%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial condition and results of operations, highlighting BRIUMVI's strong commercial performance and liquidity position Q1 2025 vs Q1 2024 Results of Operations (in thousands) | Line Item | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Product revenue, net | $119,655 | $50,488 | +137.0% | | Total Revenue | $120,856 | $63,474 | +90.4% | | Cost of revenue | $15,541 | $5,441 | +185.6% | | Total R&D | $46,362 | $32,722 | +41.7% | | Total SG&A | $50,331 | $34,581 | +45.5% | | Net income (loss) | $5,060 | ($10,707) | N/A | - The significant increase in net product revenue was due to greater market penetration of BRIUMVI in the United States[139](index=139&type=chunk) - Research and development expenses increased primarily due to manufacturing costs associated with the ublituximab subcutaneous development program[143](index=143&type=chunk) - Selling, general and administrative expenses rose due to increased costs associated with the commercialization of BRIUMVI[145](index=145&type=chunk) - The company anticipates its cash, cash equivalents, and investment securities, combined with projected BRIUMVI revenues, will provide sufficient liquidity for more than 12 months[149](index=149&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=33&type=section&id=Item%203%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes in its market risk exposure since the prior annual report - There have been no material changes in the company's market risk exposure since the last annual report[155](index=155&type=chunk) [Item 4. Controls and Procedures](index=33&type=section&id=Item%204%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the quarter[156](index=156&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[157](index=157&type=chunk) [PART II: Other Information](index=34&type=section&id=PART%20II%20OTHER%20INFORMATION) This part covers other important information including legal proceedings, detailed risk factors, equity sales, and exhibits [Item 1. Legal Proceedings](index=34&type=section&id=Item%201%20Legal%20Proceedings) The company reports no involvement in any material pending legal proceedings - The company is not currently involved in any material legal proceedings[158](index=158&type=chunk) [Item 1A. Risk Factors](index=34&type=section&id=Item%201A%20Risk%20Factors) This section extensively discusses risks and uncertainties that could adversely affect the company's business, financial condition, and operating results [Risks Related to Commercialization](index=35&type=section&id=Risks%20Related%20to%20Commercialization) This subsection details risks associated with commercializing BRIUMVI and future products, including market acceptance, competition, pricing, and product liability - Failure to achieve broad market acceptance for BRIUMVI among physicians, patients, and payors could significantly limit revenue[161](index=161&type=chunk) - The company faces substantial competition from large pharmaceutical companies with greater resources and established market presence in the neurological and immunological fields[173](index=173&type=chunk) - The business is vulnerable to unfavorable pricing regulations, cost-containment efforts by payors, and challenges in securing adequate reimbursement, which could harm profitability[177](index=177&type=chunk)[179](index=179&type=chunk) [Risks Related to Financial Position and Capital Needs](index=40&type=section&id=Risks%20Related%20to%20Our%20Financial%20Position%20and%20Need%20for%20Additional%20Capital) This subsection outlines financial risks, including a history of operating losses, potential future capital needs, and the significant indebtedness from the **$250 million** term loan - Despite recent net income, the company has a history of significant operating losses and may incur losses in the future, as profitability depends on sustained revenue from BRIUMVI[190](index=190&type=chunk)[191](index=191&type=chunk) - The company may need to raise additional capital, and an inability to do so on acceptable terms could require delaying or eliminating drug development or commercialization efforts[195](index=195&type=chunk) - The **$250 million** term loan from Blue Owl Capital imposes significant debt service obligations and restrictive covenants that could adversely affect financial condition and operational flexibility[202](index=202&type=chunk)[206](index=206&type=chunk) [Risks Related to Drug Development and Regulatory Approval](index=44&type=section&id=Risks%20Related%20to%20Drug%20Development%20and%20Regulatory%20Approval) This subsection covers inherent uncertainties of drug development, including trial success predictability, lengthy processes, potential side effects, and complex regulatory hurdles - Early-stage clinical trial results are not necessarily predictive of future success, and product candidates face a high rate of failure in later-stage trials[211](index=211&type=chunk) - Clinical development is a long, expensive, and uncertain process; delays in trial completion or negative results could prevent or delay commercialization[217](index=217&type=chunk) - Undesirable side effects from product candidates could delay or prevent regulatory approval, or if discovered post-approval, could lead to market withdrawal or a more restrictive label[226](index=226&type=chunk) [Risks Related to Dependence on Third Parties](index=62&type=section&id=Risks%20Related%20to%20Our%20Dependence%20on%20Third%20Parties) This subsection highlights the company's significant reliance on third parties for clinical trials, manufacturing, and intellectual property, posing operational and development risks - The company relies on third-party CROs to conduct clinical trials, and any failure by them to perform adequately could delay or terminate trials and jeopardize regulatory approval[286](index=286&type=chunk) - The company contracts with third parties like Samsung Biologics for the sole-source manufacture of BRIUMVI, increasing the risk of supply disruptions that could impair commercialization[290](index=290&type=chunk) - As products are in-licensed, any dispute with or non-performance by licensors (e.g., LFB Group for BRIUMVI) could adversely affect the ability to develop and commercialize the products[300](index=300&type=chunk) [Risks Related to Intellectual Property](index=68&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) This subsection discusses the critical importance and risks of intellectual property, including obtaining and defending patents, potential infringement, and protecting trade secrets - Commercial success is highly dependent on obtaining and maintaining robust patent protection for products like BRIUMVI; if patent scope is insufficient, competitors could develop similar drugs[314](index=314&type=chunk)[315](index=315&type=chunk) - The company may be involved in expensive and time-consuming lawsuits to enforce its patents or defend against claims that it infringes on third-party intellectual property[336](index=336&type=chunk)[342](index=342&type=chunk) - Failure to protect the confidentiality of trade secrets could harm the company's competitive position, as this is a primary form of intellectual property for its proprietary compound library[349](index=349&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=84&type=section&id=Item%202%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the company's share repurchase activity, including the **$100 million** authorized program and **$6.1 million** in repurchases during Q1 2025 - The company has a share repurchase program authorized for up to **$100 million** of its common stock, which was approved in August 2024[390](index=390&type=chunk) Q1 2025 Share Repurchases | Period | Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | January 2025 | 99,835 | $30.13 | | February 2025 | 94,860 | $31.28 | | March 2025 | 5,000 | $29.28 | | **Total Q1 2025** | **199,695** | **$30.23** | - As of March 31, 2025, approximately **$85.1 million** remained available for future repurchases under the program[387](index=387&type=chunk) [Item 3. Defaults Upon Senior Securities](index=85&type=section&id=Item%203%20Defaults%20of%20Senior%20Securities) The company reports no defaults upon senior securities during the period - None [Item 5. Other Information](index=85&type=section&id=Item%205%20Other%20Information) The company states that no directors or executive officers adopted or terminated Rule 10b5-1 trading plans during Q1 2025 - No directors or executive officers adopted or terminated Rule 10b5-1 trading plans during the quarter[393](index=393&type=chunk) [Item 6. Exhibits](index=85&type=section&id=Item%206%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and iXBRL data files - The exhibits include certifications from the CEO and CFO as required by the Sarbanes-Oxley Act of 2002[396](index=396&type=chunk)

Financial Performance - TG Therapeutics reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents [1] - The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million [1] Product Performance - Briumvi's U.S. net sales reached $119.7 million, demonstrating growing confidence in the treatment and increasing adoption by healthcare providers [2][3] - The company presented five-year data from the ULTIMATE I & II Phase 3 trials, showing that 92% of patients were free from disability progression after five years, with an annualized relapse rate of 0.02 during year 5 [4] - No new safety signals emerged over five years of continuous treatment, with no observed cases of progressive multifocal leukoencephalopathy (PML) [4] Future Guidance - TG Therapeutics raised Briumvi's U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance [5] - The total global revenue target was raised to $575 million from prior guidance of $540 million [5] - Briumvi's U.S. net product revenue is expected to be $135 million in the second quarter of 2025 [5] Stock Performance - TGTX stock was down 13.2% at $37.68 on Monday [6]

Core Insights - TG Therapeutics reported a significant increase in revenue and achieved profitability, but the stock price fell sharply due to investor disappointment [1][4][7] Revenue Performance - The company's revenue for the first quarter was nearly $121 million, almost double the $63.5 million from the same period in 2024, driven primarily by Briumvi sales [2][6] - Analysts had a collective revenue estimate of $117 million, indicating that the actual revenue exceeded expectations [4] Profitability - TG Therapeutics posted a net profit of just over $5 million, or $0.03 per share, compared to an almost $11 million loss in the first quarter of 2024 [4] - The consensus estimate for earnings per share was $0.16, suggesting that the actual profit fell short of analyst expectations [4][7] Pipeline Developments - The company is conducting two phase 1 trials for Briumvi: one for subcutaneous use in relapsing MS patients and another for myasthenia gravis [5] - Additionally, TG is developing a CAR T cell therapy, azercabtagene zapreleucel, which is currently in enrollment for a phase 1 trial [5] Guidance Update - TG Therapeutics raised its guidance for domestic Briumvi sales in 2025 to $560 million, up from a previous estimate of $525 million [6] - Overall revenue guidance was also increased to $575 million from $540 million [6]

Company Overview - TG Therapeutics, Inc. is a commercial stage pharmaceutical company based in Morrisville, North Carolina, known for marketing and selling Briumvi (ublituximab), which was approved in the US in 2022 for treating relapsing forms of multiple sclerosis (rMS) [2]. Market Position and Offerings - The company provides a platform for both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2]. Analyst Insights - Edmund Ingham, a biotech consultant with over 5 years of experience in the sector, has compiled detailed reports on more than 1,000 companies and leads the investing group Haggerston BioHealth [2].